# Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

> **NCT01005537** · — · NO_LONGER_AVAILABLE · sponsor: **Fred Hutchinson Cancer Center**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** therapeutic autologous lymphocytes
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT01005537
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** 2009-06
- **Primary completion:** 2010-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01005537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01005537, "Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01005537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*